The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better
Am J Prev Cardiol. 2024 Mar 18;18:100649. doi: 10.1016/j.ajpc.2024.100649. eCollection 2024 Jun.ABSTRACTCumulative exposure to low-density lipoprotein cholesterol (LDL-C) is a key driver of atherosclerotic cardiovascular disease (ASCVD) risk. An armamentarium of therapies to achieve robust and sustained reduction in LDL-C can reduce ASCVD risk. The gold standard for LDL-C assessment is ultracentrifugation but in routine clinical practice LDL-C is usually calculated and the most accurate calculation is the Martin/Hopkins equation. For primary prevention, consideration of estimated ASCVD risk frames decision making regarding...
Source: Atherosclerosis - April 5, 2024 Category: Cardiology Authors: Omar Mhaimeed Zain A Burney Stacey L Schott Payal Kohli Francoise A Marvel Seth S Martin Source Type: research
The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better
Am J Prev Cardiol. 2024 Mar 18;18:100649. doi: 10.1016/j.ajpc.2024.100649. eCollection 2024 Jun.ABSTRACTCumulative exposure to low-density lipoprotein cholesterol (LDL-C) is a key driver of atherosclerotic cardiovascular disease (ASCVD) risk. An armamentarium of therapies to achieve robust and sustained reduction in LDL-C can reduce ASCVD risk. The gold standard for LDL-C assessment is ultracentrifugation but in routine clinical practice LDL-C is usually calculated and the most accurate calculation is the Martin/Hopkins equation. For primary prevention, consideration of estimated ASCVD risk frames decision making regarding...
Source: Atherosclerosis - April 5, 2024 Category: Cardiology Authors: Omar Mhaimeed Zain A Burney Stacey L Schott Payal Kohli Francoise A Marvel Seth S Martin Source Type: research
Comparative Safety and Efficacy of Low/Moderate-Intensity Statin plus Ezetimibe Combination Therapy vs. High-Intensity Statin Monotherapy in Patients with Atherosclerotic Cardiovascular Disease: An Updated Meta-Analysis
ConclusionThis meta-analysis demonstrated that the use of low/moderate-intensity statin combination therapy significantly reduced LDL-C levels compared with high-intensity statin monotherapy, making it preferable for patients with related risks. However, further trials are encouraged to evaluate potential adverse effects associated with combined therapy. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - April 5, 2024 Category: Cardiology Source Type: research
Pharmacist optimization of lipid therapy in patients with peripheral vascular disease
CONCLUSION: The addition of a pharmacist consult led to an increase in the percentage of patients discharged on a high-intensity statin and an increase in overall statin intensification.PMID:38567808 | DOI:10.1093/ajhp/zxae097 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - April 3, 2024 Category: Drugs & Pharmacology Authors: Mary-Ashlyn Tucker Andrew Meyer Michael Bitonti Megan Supple Brandon Cain Source Type: research
Pharmacist optimization of lipid therapy in patients with peripheral vascular disease
CONCLUSION: The addition of a pharmacist consult led to an increase in the percentage of patients discharged on a high-intensity statin and an increase in overall statin intensification.PMID:38567808 | DOI:10.1093/ajhp/zxae097 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - April 3, 2024 Category: Drugs & Pharmacology Authors: Mary-Ashlyn Tucker Andrew Meyer Michael Bitonti Megan Supple Brandon Cain Source Type: research
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
CONCLUSIONS: All doses of obicetrapib taken as an adjunct to stable statin therapy significantly lowered atherogenic lipoprotein lipid parameters, showed near complete elimination of drug by 4 weeks, and were safe and well tolerated in a Japanese population, similar to previous studies of obicetrapib conducted in predominantly Caucasian participants.PMID:38569868 | DOI:10.5551/jat.64828 (Source: Atherosclerosis)
Source: Atherosclerosis - April 3, 2024 Category: Cardiology Authors: Mariko Harada-Shiba Michael H Davdison Marc Ditmarsch Andrew Hsieh Erin Wuerdeman Douglas Kling Annie Nield Mary R Dicklin Akitaka Nakata Atsushi Sueyoshi Satoshi Kuroyanagi John J P Kastelein Source Type: research
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
CONCLUSIONS: All doses of obicetrapib taken as an adjunct to stable statin therapy significantly lowered atherogenic lipoprotein lipid parameters, showed near complete elimination of drug by 4 weeks, and were safe and well tolerated in a Japanese population, similar to previous studies of obicetrapib conducted in predominantly Caucasian participants.PMID:38569868 | DOI:10.5551/jat.64828 (Source: Journal of Atherosclerosis and Thrombosis)
Source: Journal of Atherosclerosis and Thrombosis - April 3, 2024 Category: Cardiology Authors: Mariko Harada-Shiba Michael H Davdison Marc Ditmarsch Andrew Hsieh Erin Wuerdeman Douglas Kling Annie Nield Mary R Dicklin Akitaka Nakata Atsushi Sueyoshi Satoshi Kuroyanagi John J P Kastelein Source Type: research
Efficacy of Short Course Direct Acting Antivirals and Ezetimibe vs Longer Course of Direct Acting Antivirals to Prevent Hepatitis C Infection in Thoracic Transplant Recipients of Hepatitis C Viremic Donors
Purpose: Heart and lung transplantation are lifesaving procedures but are limited by the ongoing shortage of donors. Pan-genotypic direct acting antivirals (DAA) and HCV entry blockers have allowed centers to utilize HCV positive organs for HCV negative recipients, increasing the pool of available donors. However, the optimal duration of this therapy has not been established. We evaluated if a DAA combined with an HCV entry blocker given for 14 days was associated with similar outcomes compared to a regimen of DAA alone given for 28 days in preventing HCV infection in heart and lung recipients receiving organs from HCV nuc...
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , T. Fallah, B.A. Whitson, B.C. Lampert, J.P. Rosenheck, A.M. Ganapathi, M.C. Henn, N. Marschalk, K.T. Kissling Source Type: research
Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies
CONCLUSIONS: In this pooled data analysis from 3 studies in pediatric patients with HoFH, evolocumab was well tolerated, with no new safety signals reported. These safety findings are consistent with findings from previous studies of evolocumab. Patients showed marked variability in LDL-C reduction. Results from this pooled analysis support guidelines suggesting a trial of PCSK9 inhibitor therapy regardless of estimated residual LDLR function.REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01624142, NCT03403374, and NCT02624869.PMID:38545781 | DOI:10.1161/ATVBAHA.123.320268 (Source: Arteriosclerosi...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - March 28, 2024 Category: Cardiology Authors: Frederick J Raal Robert A Hegele Andrea Ruzza J Antonio G L ópez Ajay K Bhatia Johnny Wu Huei Wang Daniel Gaudet Albert Wiegman Jian Wang Raul D Santos Source Type: research
Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies
CONCLUSIONS: In this pooled data analysis from 3 studies in pediatric patients with HoFH, evolocumab was well tolerated, with no new safety signals reported. These safety findings are consistent with findings from previous studies of evolocumab. Patients showed marked variability in LDL-C reduction. Results from this pooled analysis support guidelines suggesting a trial of PCSK9 inhibitor therapy regardless of estimated residual LDLR function.REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01624142, NCT03403374, and NCT02624869.PMID:38545781 | DOI:10.1161/ATVBAHA.123.320268 (Source: Arteriosclerosi...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - March 28, 2024 Category: Cardiology Authors: Frederick J Raal Robert A Hegele Andrea Ruzza J Antonio G L ópez Ajay K Bhatia Johnny Wu Huei Wang Daniel Gaudet Albert Wiegman Jian Wang Raul D Santos Source Type: research
